Company funded to meet upcoming milestones over the next 24 months Expected FDA approval for KETARX (racemic ketamine) via the ANDA pathway in Q1-2024 and international approvals after that Company advancing PharmaPatch (microneedle patch) for psychedelics and infectious diseases Streamlined clinical development programs to focus on near-term investment and revenue opportunities with KETARX and…
